| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 04/04/2001 | EP1088100A2 Proteasomal activity |
| 04/04/2001 | EP1088098A2 Fitness assay and associated methods |
| 04/04/2001 | EP1088079A2 Nek-related and bub1-related protein kinases |
| 04/04/2001 | EP1088065A2 Antisense oligonucleotides for treating or preventing atopic diseases and neoplastic cell proliferation |
| 04/04/2001 | EP1087994A1 INTERACTION OF p27(KIP1) WITH FKBP-12 |
| 04/04/2001 | EP1087971A1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
| 04/04/2001 | EP1087970A1 PYRROLO 2,3-d]PYRIMIDINE COMPOUNDS |
| 04/04/2001 | EP1087963A1 Inhibitors of glycogen synthase kinase 3 |
| 04/04/2001 | EP1087951A1 Carbon substituted aminothiazole inhibitors of cyclin dependent kinases |
| 04/04/2001 | EP1087946A1 Aryl alkanoylpyridazines |
| 04/04/2001 | EP1087937A1 Cyclic hydroxamic acids as metalloproteinase inhibitors |
| 04/04/2001 | EP1087934A1 Aminocyclohexyl ether compounds and uses thereof |
| 04/04/2001 | EP1087791A1 Inhibition of xenoreactive antibodies |
| 04/04/2001 | EP1087787A1 Artificial t helper cell epitopes as immune stimulators for synthetic peptide immunogens including immunogenic lhrh peptides |
| 04/04/2001 | EP0636127B1 Disubstituted acetylenes bearing heterobicyclic groups and heteroaromatic or phenyl groups having retinoid like activity |
| 04/04/2001 | CN1290266A Benzofuran-4-carboxamides and their therapeutical use |
| 04/04/2001 | CN1290260A Hydroxamic and carboxylic acid derivatives |
| 04/04/2001 | CN1290255A Dihydroxyhexanoic acid derivatives |
| 04/04/2001 | CN1290174A Compositions and methods for systemic delivery of oral vaccines and therapeutic agents |
| 04/04/2001 | CN1290173A Over-expressing homologous antigen vaccine and method of making same |
| 04/04/2001 | CN1290165A Benzothiazole Protein tyrosine kinase inhibitors |
| 04/04/2001 | CN1289594A Method for treatment of diseases concerned with cytoplasmic factor |
| 04/03/2001 | US6211368 Hydrolysis of corresponding ester |
| 04/03/2001 | US6211367 Methods of Synthesing Purine Compounds Having PDE Iv Inhibitory Activity |
| 04/03/2001 | US6211352 Method for the diagnosis and treatment of glutamic acid decarboxylase autoantigen associated diseases |
| 04/03/2001 | US6211342 Multivalent MHC complex peptide fusion protein complex for stimulating specific T cell function |
| 04/03/2001 | US6211228 Compositions and methods for treating mast-cell mediated conditions |
| 04/03/2001 | US6211222 Substituted indazole derivatives and related compounds |
| 04/03/2001 | US6211200 Administering zinc chelated imidazo(4,5-d)imidazole compounds as granulocyte colony stimulating factor agonists |
| 04/03/2001 | US6211197 Carboxylic acid or tetrazole derivates; analgesics, antipyretics, and antiinflammatory agents; side effect reduction |
| 04/03/2001 | US6211182 Histamine h3-antagonists; antiinflammatory agents, antiallergens, antiasthmatics; nervous system, psychological, sleep, and gastrointestinal disorders |
| 04/03/2001 | US6211179 Treating sexual disorders, impotency, and menopause; administering purine derivative; nitric oxide synthase substrates |
| 04/03/2001 | US6211160 Method for tolerizing a mammalian patient to administration of gene therapy virus vectors |
| 04/03/2001 | US6211155 Stimulating immune system with peptides conjugated with mono-or dicarboxylic acid; |
| 04/03/2001 | US6211151 Peptides with organo-protective activity, a process for preparation thereof and their use in therapy |
| 04/03/2001 | US6210903 Amino acid sequence which is optionally modified and biotinylated |
| 04/03/2001 | US6210677 Method to reduce the physiologic effects of drugs on mammals |
| 04/03/2001 | US6210672 Topical immunostimulation to induce Langerhans cell migration |
| 04/03/2001 | US6210670 Cross-reacting monoclonal antibodies specific for E-selectin and P-selectin |
| 04/03/2001 | US6210668 Destruction of contaminating tumor cells in stem cell transplants using bispecific antibodies |
| 04/03/2001 | US6210662 Fusion protein having prostatic acid phosphatase (pap) as an n-terminal moiety and gm-csf as a c-terminal moiety, and wherein said cells are effective to activate t-cells to produce a multivalent cytotoxic cellular immune response |
| 04/03/2001 | US6210661 IL-4 receptor for the therapy, prophylaxis and diagnosis of allergic, viral, and bacterial diseases and of fungal infections |
| 04/03/2001 | US6210654 Jak kinases and regulation of cytokine signal transduction |
| 03/30/2001 | WO2003044525A1 Targeting cells having mad2 mutation for treatment and/or prevention of disease |
| 03/29/2001 | WO2001021812A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | WO2001021800A1 Monoclonal antibody 3f1h10 neutralising vhsv (viral haemorrhagic septicaemia virus) |
| 03/29/2001 | WO2001021796A2 Gl50 molecules and uses therefor |
| 03/29/2001 | WO2001021761A2 Recombinant adenoviral vectors and their utility in the treatment of various types of fibrosis: hepatic, renal, pulmonary, as well as hypertrophic scars |
| 03/29/2001 | WO2001021663A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | WO2001021660A1 Peptides for combating the autoantibodies that are responsible for dilatative cardiomyopathy (dcm) |
| 03/29/2001 | WO2001021658A1 32 human secreted proteins |
| 03/29/2001 | WO2001021628A1 A substantially cell membrane impermeable compound and use thereof |
| 03/29/2001 | WO2001021620A2 Amine derivatives of benzo-4,5-thieno-2,3-d pyrimidines |
| 03/29/2001 | WO2001021619A1 N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent |
| 03/29/2001 | WO2001021600A1 Caspase inhibitor |
| 03/29/2001 | WO2001021598A1 Therapeutic quinazoline compounds |
| 03/29/2001 | WO2001021584A1 Tyrosine derivatives |
| 03/29/2001 | WO2001021583A1 Hydroxamic acid derivatives, process for the production thereof and drugs containing the same as the active ingredient |
| 03/29/2001 | WO2001021575A1 Anti-inflammatory nitro- and thia- fatty acids |
| 03/29/2001 | WO2001021213A2 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | WO2001021210A1 Anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | WO2001021207A2 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 03/29/2001 | WO2001021204A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | WO2001021202A2 Treatment of chronic inflammatory disease by inhibiting sub-groups of activated t-cells |
| 03/29/2001 | WO2001021201A2 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen |
| 03/29/2001 | WO2001021200A1 Oral recombinant lactobacilli vaccines |
| 03/29/2001 | WO2001021199A1 Highly efficient dendritic cell-targeted dna-vaccination |
| 03/29/2001 | WO2001021193A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | WO2001021189A1 Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions |
| 03/29/2001 | WO2001021177A1 Chemokine/cytokine expression inhibitors |
| 03/29/2001 | WO2001021172A1 Anti-cancer nitro- and thia-fatty acids |
| 03/29/2001 | WO2001021162A2 Treating allergic and inflammatory conditions using desloratadine |
| 03/29/2001 | WO2001021161A2 Use of desloratadine for treating allergic and inflammatory conditions |
| 03/29/2001 | WO2001021152A1 Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant |
| 03/29/2001 | WO2000075139A3 Benzothiazinone and benzoxazinone compounds |
| 03/29/2001 | WO2000073294A3 3-(arylsulfonylamino)-tetrahydrofuran-3-carboxylic acid hydroxamides |
| 03/29/2001 | WO2000051576A3 Novel pharmaceuticals, dietary supplements and cosmetic compositions, and the use of certain mixtures for preparing a medicament or a dietary supplement for the treatment or prevention of inflammation, hypersensitivity reactions or pain |
| 03/29/2001 | WO2000047583A8 Cyclic substituted fused pyrrolocarbazoles and isoindolones |
| 03/29/2001 | WO2000037487A8 αvβ6 INTEGRIN INHIBITORS |
| 03/29/2001 | WO1999050282A3 Peptides for the treatment, prophylaxis, diagnosis and monitoring of autoimmune diseases |
| 03/29/2001 | DE19946289A1 Benzodiazepin-Derivate, deren Herstellung und Anwendung Benzodiazepine derivatives, their production and use |
| 03/29/2001 | DE19946142A1 Cell-targeting vector selective for T lymphocytes, useful in gene therapy of e.g. acquired immune deficiency syndrome, encodes a single-chain variable antibody fragment |
| 03/29/2001 | DE19945810A1 Substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel Substituted benzimidazole derivatives, processes for their preparation and their use as medicaments |
| 03/29/2001 | DE19944767A1 N-substituierte 4-Aminopteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel N-substituted 4-Aminopteridine, processes for their preparation and their use as medicaments |
| 03/29/2001 | CA2847143A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2805979A1 Inhibition of secretiion from non-neuronal cells |
| 03/29/2001 | CA2404709A1 Highly efficient dendritic cell-targeted dna-vaccination |
| 03/29/2001 | CA2387520A1 Amine derivatives |
| 03/29/2001 | CA2385552A1 Phosphatases which activate map kinase pathways |
| 03/29/2001 | CA2385480A1 32 human secreted proteins |
| 03/29/2001 | CA2385425A1 Pcna associated cell cycle proteins, compositions and methods of use |
| 03/29/2001 | CA2384806A1 Use of replication-deficient adenoviral vector to boost cd8+ t cell immune response to antigen |
| 03/29/2001 | CA2383629A1 Hybrid peptides modulate the immune response |
| 03/29/2001 | CA2383598A1 Therapeutic uses of m3 polypeptide |
| 03/29/2001 | CA2383589A1 Anionic amino acid based surfactants to enhance antimicrobial effectiveness of topical pharmaceutical compositions |
| 03/29/2001 | CA2383470A1 Inhibition of secretion from non-neuronal cells |
| 03/29/2001 | CA2383462A1 Therapeutic methods and compounds |
| 03/29/2001 | CA2383433A1 Oral recombinant lactobacilli vaccines |
| 03/29/2001 | CA2383413A1 Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines |
| 03/29/2001 | CA2383214A1 Treating allergic and inflammatory conditions |